Total : 58 View more »
An investigation into a company that has claimed rosy results for a non-invasive test for Down's syndrome reveals errors and unsubstantiated assertions
http://www.newscientist.com/article/mg20427292.800-downs-blood-test-hits-speed-bump.html
MedSpeed, a provider of integrated transportation services, has partnered with Sequenom Center for Molecular Medicine (Sequenom CMM) to manage and execute its national transportation services.
http://www.logistics-business-review.com/news/medspeed_collaborates_with_sequenom_cmm_091028
"I am delighted that Paul has agreed to join Sequenom as our interim CFO," said Dr. Hixson. "His wealth of experience, including over 20 years in the pharmaceutical and biotechnology industry makes him an ideal fit for us.
Shares of the biotech group tumble more than 44% in late trading after the company fires its chief executive and other officers following an inquiry into mishanded data.
http://www.marketwatch.com/story/sequenom-shares-plunge-after-ceo-others-fired-2009-09-28-191300
Total : 38 View more »
Nov 16, 2009 (SmarTrend(R) Spotlight via COMTEX) --
SmarTrend, our proprietary pattern recognition system, called a Downtrend for Sequenom (NASDAQ:SQNM) on September 29, 2009 at $3.57.
Since then, Sequenom has returned 10.4% as of today's recent price of $3.20. Want to profit from these alerts?
Go to www.mysmartrend.com now for a FREE two-week trial.
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html
Tags: market nasdaq profit securities trial
Companies: Sequenom inc (SQNM)
DALLAS, Nov 17, 2009 (GlobeNewswire via COMTEX) --
StockPreacher.com announces an investment report featuring biotechnology company Sequenom Inc. (Nasdaq:SQNM). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Sequenom Inc. (Nasdaq:SQNM) should be of particular interest to comparable companies: Illumina Inc. (Nasdaq:ILMN), Clinical Data Inc. (Nasdaq:CLDA), Affymetrix Inc. (Nasdaq:AFFX) and Invitrogen Corp. (Nasdaq:IVGN).
The full report is available at: http://www.stockpreacher.com/n/SQNM
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Sequenom Inc. (SQNM) provides products, services, diagnostic testing, applications, and genetic analysis products that translate genomic science into solutions for biomedical research, translational research, molecular medicine, and agricultural and livestock applications. It offers MassARRAY system, a high performance nucleic acid analysis platform that measures genetic target material and variations.
Message Board Search for SQNM: http://www.boardcentral.com/boards/SQNM
In the report, the analyst notes:
"The Company recently launched this new version of the MassARRAY system, which addresses the needs of lower throughput laboratories. The new MassARRAY Compact 96 system offers accuracy, sensitivity, and the ability to cost-effectively run fewer samples making this an ideal system for validation of candidate genetic markers in basic research and clinical research laboratories. As a result of the introduction of MassARRAY Compact 96 system, SQNM is beginning to see traction in clinical research settings, where its technology is ideally suited for the validation of candidate genetic markers.
"In September, SQNM fired its CEO and four others after an independent panel of directors found the Company failed to adequately police its studies of a noninvasive prenatal Down Syndrome test. The Company had been preparing to launch the Down syndrome test SEQureDx in June, but had to delay because of employee mishandling of test data and results. The independent investigation has been concluded and a new senior management team has been put in place. Currently, the Company is rigorously evaluating multiple RNA and DNA technologies for use in the development of its trisomy 21 (T21) test. In terms of clinical activities, SQNM is sponsoring three ongoing T21 studies."
To read the entire report visit: http://www.stockpreacher.com/n/SQNM
See what investors are saying about these stocks at: http://www.stockhideout.com/
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: StockPreacher
CONTACT: StockPreacher.com Jeff Bishop (469)-252-3505 press@beaconequity.com
Tags: advisor agricultural biomedical biotechnology ceo clinical dna investigation investment investment opinion livestock medicine nasdaq police products research science securities small cap technology web
Companies: Affymetrix, Inc. (AFFX), Illumina, Inc. (ILMN), Invitrogen Corp. (IVGN), Sequenom inc (SQNM)
Nov 10, 2009 (SmarTrend(R) Spotlight via COMTEX) --
Sequenom (NASDAQ:SQNM) maintained Sell, $3 target, at Auriga. The stock closed yesterday at $3.28 on volume of 2,022,000 shares, below average daily volume of 7,742,128.
Sequenom is currently below its 50-day moving average of $4.34 and below its 200-day moving average of $8.14.
SmarTrend is bearish on shares of SQNM and our subscribers received a Downtrend alert on September 29, 2009 at $3.57, which has returned 8.1% to date.
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html
Tags: market nasdaq securities
Companies: Sequenom inc (SQNM)
Nov 09, 2009 (Wall Street Horizon via COMTEX) --
Sequenom Inc. (SQNM)
Expected next earnings release: Announcement date: 11/9/2009 - After Market Earnings Quarter: Q3 Announcement Status: Verified
Expected next investor conference call information: Conference Call Date: 11/9/2009 Conference Call Time (ET): 4:30 PM Conference Call URL: http://www.sequenom.com/Corporate/Webcasts
Tags: conference corporate earnings market
Companies: Sequenom inc (SQNM)
Total : 91 View more »
...SAN DIEGO Oct. 26 /- Sequenom Inc. (Nasdaq: ...(Logo: a href'http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO...Prior to the effective date of Mr. Maier's appointment as interim chie... I am delighted that Paul has agreed to join Sequenom as our interim
Tuesday Afternoon, 15 January 2002 4:00 pm - 6:15 pm Sequenom Workshop - Golden Ballroom Organizer: Tanya Boyaniwsky, Sequenom (tboyaniw@sequenom.com) Speakers: Christian Jurinke, Sequenom (cjurinke@sequenom.com) John McEwan, AgResearch (john.mcewan@agresearch.co.nz) Korena Paterson, AgResearch
Sequenom, Inc. a provider of genetic analysis solutions, announced the launch of the iSEQ™ application software, a MassARRAY® comparative sequence analysis application for automated, high-throughput identification and typing of microbes and viruses, as well as human disease-related molecular
http://www.dddmag.com/product-iSEQ-Application-Software-708.aspx
Interview and discussion with Raghuram Selvaraju of the Hapoalim Securities, talking about Sequenom's economic situation. (Bloomberg News) http://www.clipsyndicate.com/video/playlist/1998/1116869?cpt=8&wpid=523
http://www.zibb.com/article/5556404/Video+In+Depth+Look+Sequenom+s+Shocker
Total : 357 View more »
Sequenom Incorporated. The Group's principal activity is providing genetic analysis products that translate genomic science into superior solutions for non-invasive prenatal ...
http://www.corporateinformation.com/Company-Snapshot.aspx?cusip=817337405
Sequenom Incorporated. The Group's principal activity is providing genetic analysis products that translate genomic science into superior solutions for non-invasive prenatal ...
http://wrightreports.ecnext.com/coms2/reportdesc_COMPANY_817337405
Get the latest SQNM - Sequenom Incorporated stock market performance data. TheStreet is the source for financial market news, trading stock, quotes, and personal finance advice.
Sequenom is committed to providing the best genomic and genetic analysis solutions for the research and molecular diagnostic markets. We provide Genetic Analysis Systems for SNP ...